FGF19 protects skeletal muscle against obesity‐induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT‐1/PGC‐α pathway

Obesity is associated with biological dysfunction in skeletal muscle. As a condition of obesity accompanied by muscle mass loss and physical dysfunction, sarcopenic obesity (SO) has become a novel public health problem. Human fibroblast growth factor 19 (FGF19) plays a therapeutic role in metabolic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Cell Mol Med
Hlavní autoři: Guo, Ai, Li, Kai, Tian, Hong‐Chuan, Fan, Zhen, Chen, Qiu‐Nan, Yang, Yun‐Fei, Yu, Jing, Wu, Yong‐Xin, Xiao, Qian
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034456/
https://ncbi.nlm.nih.gov/pubmed/33751819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.16448
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky